Pharmaceutical compositions and methods for anesthesiological applications
Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions including a benzodiazepine-based compound, an NMDA antagonist, and optionally a β-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Compositions may be incorporated into vehicles for extended release. Methods for fabricating the compositions and using them for anesthesiological applications are also described.
1. A solid pharmaceutical composition formulated for buccal and/or sublingual administration comprising a therapeutically effective dose of midazolam and a therapeutically effective dose of ketamine.
2. The solid pharmaceutical composition of claim 1 , wherein the quantity of the midazolam in the pharmaceutical composition is between about 0.2 mass % and about 5% mass % of the composition.
3. The solid pharmaceutical composition of claim 1 , wherein the quantity of the ketamine in the pharmaceutical composition is between about 1.0 mass % and about 10% mass % of the composition.
4. The solid pharmaceutical composition of claim 1 , further comprising a third pharmaceutically active compound selected from the group consisting of β-blockers, antiemetic medicaments, NSAIDs, antihistamines, α-2-adrenergic agonists, pain relievers and combinations thereof, or pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof.
5. The solid pharmaceutical composition of claim 1 , wherein the solid dosage form of the composition is selected from the group consisting of a troche, a lozenge, a capsule, a pill, a cap and a bolus.
6. The solid pharmaceutical composition of claim 1 , further comprising a binder.
7. The solid pharmaceutical composition of claim 6 , wherein the binder is a polyglycol selected from the group consisting of polyethylene glycol, polyethylene oxide, methoxypolyethylene glycol, polypropylene glycol and polybutylene glycol.
8. The solid pharmaceutical composition of claim 6 , wherein the binder comprises a product having a molecular weight that is sufficient to provide the necessary hardness and time for dissolution of the solid item, the binder being selected from the group consisting of methoxypolyethylene glycol, polypropylene glycol, polybutylene glycol, PEG-laureates, PEG-dilaureates, PEG-oleates, PEG-dioleates, PEG-trioleates, PEG-stearates, PEG-distearates, castor oil derivatives of PEG, palm kernel oil derivatives of PEG, corn oil derivatives of PEG, soya oil derivatives of PEG, cholesterol derivatives of PEG, phytosterol derivatives of PEG, caprate/caprylate glycerides derivatives of PEG, tocopheryl succinate derivatives of PEG, octylphenol derivatives of PEG, nonylphenol derivatives of PEG, polyglyceryl-10-laurate, polyglyceryl-10-oleate, POE-lauryl ethers, POE-oleyl ethers, POE-stearyl ethers, polysorbates, monostearate, monolaurate and monopalmitate derivatives of sucrose, and products of poly(oxypropylene)-co-poly(propylene oxide) family.
9. The solid pharmaceutical composition of claim 1 , further comprising an excipient selected from the group consisting of gelatin, sodium saccharin, stevioside, peppermint oil, cherry flavor, lemon oil, raspberry flavor and combinations thereof.
10. A solid pharmaceutical composition formulated for buccal and/or sublingual administration comprising a therapeutically effective dose of midazolam and a therapeutically effective dose of ketamine, wherein the therapeutically effective dose of midazolam comprises about 3 mg of midazolam and wherein the therapeutically effective dose of ketamine comprises about 50 mg of ketamine.
11. The solid pharmaceutical composition of claim 10 , further comprising a third pharmaceutically active compound selected from the group consisting of β-blockers, antiemetic medicaments, NSAIDs, antihistamines, α-2-adrenergic agonists, pain relievers and combinations thereof, or pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof.
12. The solid pharmaceutical composition of claim 10 , wherein the solid dosage form of the composition is selected from the group consisting of a troche, a lozenge, a capsule, a pill, a cap and a bolus.
13. The solid pharmaceutical composition of claim 10 , further comprising a binder.
14. The solid pharmaceutical composition of claim 13 , wherein the binder is a polyglycol selected from the group consisting of polyethylene glycol, polyethylene oxide, methoxypolyethylene glycol, polypropylene glycol and polybutylene glycol.
15. The solid pharmaceutical composition of claim 13 , wherein the binder comprises a product having a molecular weight that is sufficient to provide the necessary hardness and time for dissolution of the solid item, the binder being selected from the group consisting of methoxypolyethylene glycol, polypropylene glycol, polybutylene glycol, PEG-laureates, PEG-dilaureates, PEG-oleates, PEG-dioleates, PEG-trioleates, PEG-stearates, PEG-distearates, castor oil derivatives of PEG, palm kernel oil derivatives of PEG, corn oil derivatives of PEG, soya oil derivatives of PEG, cholesterol derivatives of PEG, phytosterol derivatives of PEG, caprate/caprylate glycerides derivatives of PEG, tocopheryl succinate derivatives of PEG, octylphenol derivatives of PEG, nonylphenol derivatives of PEG, polyglyceryl-10-laurate, polyglyceryl-10-oleate, POE-lauryl ethers, POE-oleyl ethers, POE-stearyl ethers, polysorbates, monostearate, monolaurate and monopalmitate derivatives of sucrose, and products of poly(oxypropylene)-co-poly(propylene oxide) family.
16. The solid pharmaceutical composition of claim 10 , further comprising an excipient selected from the group consisting of gelatin, sodium saccharin, stevioside, peppermint oil, cherry flavor, lemon oil, raspberry flavor and combinations thereof.